To determine if the SRC family kinase (SFK)-rapidly accelerated fibrosarcoma (RAF)-MEK pathway led to FRA-1 phosphorylation we treated cells with multiple small molecule kinase inhibitors that individually target each component of this pathway to identify optimal inhibitor concentrations, thus reducing the possibility of off-target effects. The gene discussed is MAP2K7; the disease is fibrosarcoma.